Bosh sahifaBSX • NYSE
add
Boston Scientific Corp
102,71 $
Seans yopilganidan keyin:(0,00%)0,00
102,71 $
Yopilgan:12-sen, 16:32:01 (GMT-4) · USD · NYSE · Ogohlantirish
Yopilish kursi
104,34 $
Kunlik diapazon
102,48 $ - 104,43 $
Yillik diapazon
80,64 $ - 109,50 $
Bozor kapitalizatsiyasi
152,19 mlrd USD
Oʻrtacha hajm
6,27 mln
Narx/foyda
61,15
Dividend daromadliligi
-
Asosiy maydon
NYSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | iyn, 2025info | Y/Y qiyosi |
---|---|---|
Daromad | 5,06 mlrd | 22,84% |
Joriy xarajat | 2,47 mlrd | 20,81% |
Sof foyda | 797,00 mln | 145,99% |
Sof foyda marjasi | 15,75 | 100,38% |
Har bir ulushga tushum | 0,75 | 20,97% |
EBITDA | 1,28 mlrd | 15,23% |
Amaldagi soliq stavkasi | 15,52% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | iyn, 2025info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 534,00 mln | -81,67% |
Jami aktivlari | 41,56 mlrd | 11,99% |
Jami passivlari | 18,91 mlrd | 14,59% |
Umumiy kapital | 22,65 mlrd | — |
Tarqatilgan aksiyalar | 1,48 mlrd | — |
Narxi/balansdagi bahosi | 6,89 | — |
Aktivlardan daromad | 5,77% | — |
Kapitaldan daromad | 6,85% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | iyn, 2025info | Y/Y qiyosi |
---|---|---|
Sof foyda | 797,00 mln | 145,99% |
Operatsiyalardan naqd pul | 1,29 mlrd | 58,18% |
Sarmoyadan naqd pul | -1,13 mlrd | -315,50% |
Moliyadan naqd pul | -340,00 mln | -1 516,67% |
Naqd pulning sof oʻzgarishi | -178,00 mln | -131,45% |
Boʻsh pul | 1,16 mlrd | 111,56% |
Haqida
Boston Scientific Corporation, is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
Tashkil etilgan
29-iyn, 1979
Xodimlar soni
53 000